Study on COPD Corticosteroid-induced Hyperglycemia on Clinical Outcome in Patients With COPD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00605007|
Recruitment Status : Completed
First Posted : January 30, 2008
Last Update Posted : November 21, 2013
|Condition or disease|
We hypothesize that COPD patients with corticosteroid-induced hyperglycemia experience higher morbidity (infections, ventilator associated pneumonia, length of stay, acute renal failure) and mortality compared to COPD patients with normal glucose levels.
To determine the impact of corticosteroid-induced hyperglycemia on clinical outcome (length of stay, disposition, APACHE score, need for ventilatory support and ICU admission, mortality) in patients with COPD exacerbation.
|Study Type :||Observational|
|Actual Enrollment :||450 participants|
|Official Title:||The Impact of Corticosteroid-induced Hyperglycemia on Clinical Outcome (Length of Stay, Disposition, APACHE Score, Need for Ventilatory Support and ICU Admission, Mortality) in Patients With COPD Exacerbation|
|Study Start Date :||February 2006|
|Actual Primary Completion Date :||June 2009|
|Actual Study Completion Date :||December 2009|
- The primary outcome of the study is to determine the mortality rate of COPD patients with corticosteroid-induce hyperglycemia. [ Time Frame: once all charts have been reviews ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00605007
|United States, Georgia|
|Grady Memorial Hospital|
|Atlanta, Georgia, United States, 30303|
|Principal Investigator:||Guillermo Umpierrez, MD||Emory University SOM|